References
Battaglia Parodi M, Romano F, Arrigo A, Di Nunzio C, Buzzotta A, Alto G, Bandello F (2020) Natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study. Graefes Arch Clin Exp Ophthalmol 258:297–301
Battaglia Parodi M, Iustulin D, Russo D et al (1996) Adult-onset foveomacular vitelliform dystrophy and indocyanine green videoangiography. Graefes Arch Clin Exp Ophthalmol 234:208–211
Battaglia Parodi M, Romano F, Cicinelli MV et al (2018) Retinal vascular impairment in best Vitelliform macular dystrophy assessed by means of optical coherence tomography angiography. Am J Ophthalmol 187:61–70
Battaglia Parodi MB, Arrigo A, Bandello F (2020) Optical coherence tomography angiography quantitative assessment of macular neovascularization in best Vitelliform macular dystrophy. Invest Ophthalmol Vis Sci 61(6):61
Battaglia Parodi M, Iacono P, Del Turco C, Bandello F (2014) Near-infrared fundus autofluorescence in subclinical best vitelliform macular dystrophy. Am J Ophthalmol 158(6):1247–1252.e2
Battaglia Parodi M, Iacono P, Romano F, Bandello F (2018) Spectral domain optical coherence tomography features in different stages of best vitelliform macular dystrophy. Retina. 38:1041–1046
Parodi MB, Romano F, Sacconi R, Casati S, Marchini G, Bandello F, Iacono P (2018) Intraretinal hyperreflective foci in best vitelliform macular dystrophy. Retina. 38:2379–2386
Khan KN, Islam F, Moore AT, Michaelides M (2018) The fundus phenotype associated with the p.Ala243Val Best1 mutation. Retina. 38:606–613
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Financial disclosures
Francesco Bandello consultant for: Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc. (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, USA). All other authors have no disclosures to declare.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Parodi, M.B., Arrigo, A. & Bandello, F. Reply: natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study. Graefes Arch Clin Exp Ophthalmol 259, 789–790 (2021). https://doi.org/10.1007/s00417-020-04890-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-020-04890-7